CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Boya Bio-pharmaceutical Group Co Ltd Company Snapshot
Boya Bio-pharmaceutical Group Co Ltd operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Boya Bio-pharmaceutical Group Co Ltd with three other companies in this sector in CHINA : Shanghai Raas Blood Products Company Limited (2019 sales of 2.58 billion Chinese Renmimbi [US$362.65 million] of which 100% was Blood products production and sales), Beijing Tiantan Biologic. (3.28 billion Chinese Renmimbi [US$460.41 million] of which 100% was Blood products), and Tonghua Dongbao Medicines Company Limited (2.78 billion Chinese Renmimbi [US$389.39 million] of which 95% was Pharmaceutical).

Sales Analysis. Boya Bio-pharmaceutical Group Co Ltd reported sales of 2.91 billion Chinese Renmimbi (US$408.07 million) for the year ending December of 2019. This represents an increase of 18.7% versus 2018, when the company's sales were 2.45 billion Chinese Renmimbi. Sales at Boya Bio-pharmaceutical Group Co Ltd have increased during each of the previous five years (and since 2014, sales have increased a total of 564%). Sales of Other Mainbusiness saw an increase that was more than double the company's growth rate: sales were up 313.3% in 2019, from 5.47 million Chinese Renmimbi to 22.60 million Chinese Renmimbi. Boya Bio-pharmaceutical Group Co Ltd also saw significant increases in sales in Bio-Pharmaceuticals (up 28.6% to 903.05 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Boya Bio-pharmaceutical Group Co Ltd
  Stock Performance Chart for Boya Bio-pharmaceutical Group Co Ltd
 
  Stock Data: Recent Stock Performance:
  Current Price (5/29/2020): 31.82
(Figures in Chinese Renmimbi)
1 Week 0.5%   13 Weeks 2.1%  
4 Weeks -9.4%   52 Weeks 17.8%  
 
Boya Bio-pharmaceutical Group Co Ltd Key Data:
  Ticker: 300294 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2019 Sales 2,908,769,255
(Year Ending Jan 2020).
Employees: 1,611
  Currency: Chinese Renmimbi Market Cap: 13,788,397,141
  Fiscal Yr Ends: December Shares Outstanding: 433,324,863
  Share Type: A Gu Closely Held Shares:
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.